ArticleBiosensors2015
Application of xCELLigence RTCA Biosensor Technology for Revealing the Profile and Window of Drug Responsiveness in Real Time.
Article in Biosensors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed.
- xCELLigence™ RTCA system in cancer biology: innovations in real-time functional profiling.Cytotechnology · 2026Review
- Reverse engineering of BNIP3 identifies a mitochondrial protective peptide.Nature communications · 2026Article
- Article
- Robust high-sensitivity real-time impedance analysis for neutralization drug screening and toxicity kinetics ofFrontiers in microbiology · 2026Article
- Cerium Phosphate Nanoparticles: Synthesis, Characterization, Biocompatibility, Regenerative Potential, and Antioxidant Activity.Molecules (Basel, Switzerland) · 2025Article
- Mechano-chemical encapsulation of gemcitabine hydrochloride on metal-organic framework, preparation of shaped pellets, delayed drug release, and time-dependent toxicity to PANC-1 cancer cells.Journal of drug delivery science and technology · 2025Article
- Exploring the Heterogeneity of Cancer-Associated Fibroblasts via Development of Patient-Derived Cell Culture of Breast Cancer.International journal of molecular sciences · 2025Article
- Article
- UHRF1 phase separation mediates stable inheritance of DNA methylation and promotes the proliferation of prostate cancer cells.Cell communication and signaling : CCS · 2025Article
- Amyloid beta-induced signalling in leptomeningeal cells and its impact on astrocyte response.Molecular and cellular biochemistry · 2025Article
- Proliferation and metabolic activity of the Atlantic sturgeon cell line AOXlar7y under short-term serum-reduced conditions, and the effect of stimulation with growth factors and cytokines.Frontiers in toxicology · 2025Article
- Dielectrophoretic characterization of peroxidized retinal pigment epithelial cells as a model of age-related macular degeneration.BMC ophthalmology · 2024Article
- Encapsulation of Gemcitabine on Porphyrin Aluminum Metal-Organic Framework by Mechano-Chemistry, Delayed Drug Release and Cytotoxicity to Pancreatic Cancer PANC-1 Cells.Molecules (Basel, Switzerland) · 2024Article
- Review
- Charting the Cannabis plant chemical space with computational metabolomics.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Improving the power of drug toxicity measurements by quantitative nuclei imaging.Cell death discovery · 2024Article
- Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p.Scientific reports · 2024Article
- Article
- Functional assay for assessment of pathogenicity of BAP1 variants.Human molecular genetics · 2024Article
- BRAF inhibitor candidate molecule usnic acid might use both intrinsic and extrinsic pathways of apoptosis.Turkish journal of medical sciences · 2024Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The xCELLigence technology is a real-time cellular biosensor, which measures the net adhesion of cells to high-density gold electrode arrays printed on custom-designed E-plates. The strength of cellular adhesion is influenced by a myriad of factors that include cell type, cell viability, growth, migration, spreading and proliferation. We therefore hypothesised that xCELLigence biosensor technology would provide a valuable platform for the measurement of drug responses in a multitude of different experimental, clinical or pharmacological contexts. In this manuscript, we demonstrate how xCELLigence technology has been invaluable in the identification of (1) not only if cells respond to a particular drug, but (2) the window of drug responsiveness. The latter aspect is often left to educated guess work in classical end-point assays, whereas biosensor technology reveals the temporal profile of the response in real time, which enables both acute responses and longer term responses to be profiled within the same assay. In our experience, the xCELLigence biosensor technology is suitable for highly targeted drug assessment and also low to medium throughput drug screening, which produces high content temporal data in real time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.